FF-10502, a structural analog of Gemcitabine, is a pyrimidine nucleoside antimetabolite. FF-10502 inhibits DNA polymerase α and β. FF-10502 shows beneficial anticancer activity via a mechanism of action on dormant cells[1].
in vivo
FF-10502 (120-480 mg/kg; i.v; once weekly; for 4 weeks) shows an antitumor effect in a mouse xenograft model with the subcutaneously implanted human pancreatic cancer cell line Capan-1[1].
Animal Model:
Five-week-old female nude mice (BALB/c-nu/nu) injected with Capan-1 cells[1].
Dosage:
120 mg/kg, 240 mg/kg, 360 mg/kg, and 480 mg/kg
Administration:
Tail vein injection; once weekly; for 4 weeks
Result:
Suppressed tumor growth in a dose-dependent manner in mice.
References
[1] Shinji Mima, et al. FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135. DOI:10.1124/jpet.118.248740
